Login to Your Account



'We've got something pretty special here'

Obsidian sharpens focus on CAR T, lands $49.5M for gene therapies

By Marie Powers
News Editor

Wednesday, December 6, 2017

Michael Gilman keeps staring down retirement. The scientist and serial entrepreneur, late of Padlock Therapeutics Inc., which was sold last year to Bristol-Myers Squibb Co. for $600 million, has been splitting his time between Arrakis Therapeutics Inc., where he serves as CEO, and an Atlas Venture company focused on gene and cell therapy. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription